Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of
androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry cancer-killing substances to them. Giving
antihormone therapy together with ipilimumab may kill more tumor cells.
PURPOSE: This randomized phase II trial is study how well giving hormone therapy and
ipilimumab together works in treating patients with advanced prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Medarex National Cancer Institute (NCI) U.S. Army Medical Research Acquisition Activity United States Department of Defense